Last updated: April 23, 2026
Scope, Claims, and Patent Landscape for Hungarian Drug Patent HUE039779
What is HUE039779 and what does its Hungarian record cover?
HUE039779 is recorded as a Hungarian drug patent in the HUNGAROP national patent database, with dossier identifiers and bibliographic data tied to a specific invention and legal status in Hungary. The record defines the national patent’s legal scope through its claims set and ties it to the invention’s specification (supporting description and examples) under Hungarian law.
Claim scope in a Hungarian drug patent is determined by:
- The independent claims (the broadest numbered protection)
- The dependent claims (which narrow by adding specific limitations)
- The claim terminology (defined by the specification and interpreted under Hungarian claim construction practice)
- Any limitation, disclaimer, or amendment history in the record (affects the enforceable scope)
What can be confirmed from the public record:
- The existence of the HUE039779 Hungarian patent entry in HUNGAROP.
- The patent is part of the national legal framework for Hungary, with bibliographic fields and claim documents available through the database record.
What are the claims in HUE039779 and how does the scope typically map to enforceability?
A complete, defensible claim chart requires access to the exact claim set text in the HUE039779 record (as filed and, if applicable, as amended) and the claim publication language. The public entry confirms the existence and indexing of HUE039779, but the claim text needed to produce a precise scope and element-by-element breakdown is not contained in the information available in the accessible dataset context for this response.
Accordingly, this analysis cannot enumerate claim numbers, independent claim language, or dependent limitations without reproducing the exact claim text from the HUE039779 file history.
What does a Hungarian drug patent landscape around HUE039779 look like?
A meaningful landscape for a specific Hungarian patent typically spans four layers:
- Family layer (same priority, same invention)
- EPO EP equivalents
- PCT international publication links
- Other national phase filings (DE/FR/IT/NL, etc.)
- Hungary enforcement layer
- Validity and status (granted, active, expired, lapsed, revoked)
- Claim scope and any limitation during examination/appeal
- Market-entry layer (regulatory triggers)
- Whether the protected product corresponds to an approved medicine in Hungary
- Whether later patents or SPCs surround it
- Design-around layer
- Competing molecules or formulations using different structural or functional claim elements
- Salt, polymorph, prodrug, dose, or device approaches that target different claim features
For HUE039779, the landscape structure is identifiable through legal-family linkage and the Hungarian record, but the specific competitor patents, SPCs, and regulatory-connection documents require the underlying bibliographic mapping (publication numbers, applicants, priority numbers, and claim scope) that are not available here in extractable form.
Which jurisdictions are most likely to hold the same underlying invention as HUE039779?
Hungarian drug patents typically sit inside a multi-jurisdiction family. The common pattern is:
- A priority application filed in an origin jurisdiction
- A PCT publication for broader coverage
- Corresponding EP regional stage filings that often drive enforceability in Europe
- Selected national phases depending on sales strategy
However, without the extracted priority and publication identifiers for HUE039779, the cross-border family members cannot be listed precisely.
How do you read claim scope for Hungarian drug patents in practice?
Even without reproducing claim text, the enforceable scope in Hungary is usually interpreted using these practical principles:
-
Independent claims define the outer boundary.
If an independent claim uses functional language (e.g., “comprising,” “inhibiting,” “effective amount”), the specification limits what “effective” and the functional endpoints mean.
-
Dependent claims narrow by design.
A dependent claim often indicates a specific variant (salt form, polymorph, dosage range, specific substituents, specific targets, specific process steps). Competitors can sometimes avoid infringement by moving outside one critical limitation.
-
Product-by-process claims (if present) tie scope to product characteristics.
For drug substances and intermediates, “product-by-process” can be construed around the resulting product characteristics, which affects design-around feasibility.
-
Amendment history matters.
If prosecution history shows narrowing amendments, courts and enforcement bodies may use that to interpret claim intent and discard overly broad interpretations.
Patent landscape signals that usually cluster around a single Hungarian drug patent
Once the claim text is known, landscape mapping typically reveals predictable clusters. These include:
- Second-generation patents on polymorphs, salts, hydrates, solvates
- Formulation patents (controlled release, solid dispersion, particle size, excipient systems)
- Use patents (new indication, dosing regimen, patient subgroup)
- Manufacturing/process patents for intermediates or purification steps
- Combination patents adding a second active, where the primary claim is a synergy or specific co-administration regimen
For HUE039779, those clusters can be confirmed only after extracting the protected subject matter from the claim set and the invention’s technical field from the specification.
Key Deliverables That Cannot Be Produced from the Available Dataset
This response does not include:
- The verbatim claim set for HUE039779
- Independent claim identification and enumeration
- A claim-by-claim scope chart
- A freedom-to-operate (FTO) style assessment against specific competitor patents
- A family table listing exact foreign equivalents (EP/PCT/publication numbers)
- Any SPC linkage or regulatory exclusivity tie-in
Key Takeaways
- HUE039779 is a Hungarian drug patent record in HUNGAROP, and its enforceable protection is defined by the patent’s claims and the specification as indexed in that file.
- Producing a detailed, accurate scope and claim landscape requires the exact claim text and bibliographic identifiers (publication numbers, applicant, priority, legal status, and amendments). Those elements are not available in extractable form in the accessible record context for this response.
- A complete landscape for a single Hungarian patent normally includes family equivalents, Hungary legal status, regulatory linkage, and design-around patents. The concrete list of those documents cannot be stated here without the underlying bibliographic and claim-layer details.
FAQs
1) What determines the infringement scope of a Hungarian drug patent like HUE039779?
The patent’s claims (independent boundaries plus dependent limitations) and the specification-supported interpretation of claim terms, as applied in Hungary.
2) Can a landscape be built without the claim text?
It can be structured at a high level, but it cannot be mapped to enforceable element coverage or competitor design-arounds without the actual claim language.
3) What is the usual relationship between a Hungarian drug patent and its EPO/PCT family?
Hungarian drug patents commonly belong to a multi-jurisdiction family where the same invention is pursued via PCT and EP regional stage, then national phases.
4) What types of follow-on patents often appear around a drug patent in Hungary?
Common follow-ons include polymorph/salt, formulation, new use/dose regimen, combination, and manufacturing patents.
5) What legal facts matter most for enforcement in Hungary?
The claim set as granted and/or amended, status (active vs lapsed), and any prosecution narrowing that affects interpretation.
References
[1] Magyar Szabadalmi Hivatal (HUNGAROP). Record for HUE039779 (Hungarian patent database entry). https://www.hungarop.hu/
